search
Back to results

Cognitive Behavioural Therapy Software for the Treatment of Depression in People With Multiple Sclerosis (CoSMoS)

Primary Purpose

Depression, Multiple Sclerosis

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
CBT Software
Treatment as usual
Sponsored by
University of Sheffield
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Depression focused on measuring CBT-software, Computerised Cognitive Behavioural Therapy, CCBT, Cognitive Therapy, Therapy, Computer-Assisted, Depression, Multiple Sclerosis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Aged 18+
  • Diagnosis of MS confirmed by neurologist
  • Beck Depression Inventory-II score of at least 14 on two consecutive occasions
  • Not currently or within past three months receiving any treatment from a psychologist, psychotherapist or psychiatrist.
  • Willingness to be randomised to CCBT, at home or primary care facility or treatment as usual.

Exclusion Criteria:

  • Unable to read or write English
  • Beck Depression Inventory score of at least 29 on two consecutive occasions
  • Active suicidal ideas
  • Current or life-time diagnosis of any of the following:

    • psychosis
    • organic mental disorder;
    • alcohol or drug dependency
  • Kurtzke Expanded Disability Status Scale (EDSS) score of 8.5 or above
  • Unable to use the CCBT package due to physical disability
  • Unable to use the CCBT package due to cognitive symptoms (mini-mental state of 20 below or if, in the opinion of the study psychologist, the individual would be unlikely to benefit from CCBT)

Sites / Locations

  • Sheffield Teaching Hospitals NHS Foundation Trust

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

1

2

Arm Description

CBT software delivered at home or in a primary care facility (n=12)

Treatment as usual (n=12)

Outcomes

Primary Outcome Measures

Change in Self-reported Symptoms of Depression, as Measured by Total BDI-II Score
Beck Depression Inventory II-21 Item (BDI-II) - a self-report measure of severity of symptoms of depression. This is scored by summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The maximum total score is 63 (severe depression). The study reports change from baseline at 21 weeks.

Secondary Outcome Measures

Change in Disease-specific Quality of Life, Measured on the Multiple Sclerosis Impact Scale-29 Item (MSIS-29)
The Multiple Sclerosis Impact Scale (MSIS-29) is a 29-item self-report measure with 20 items associated with a physical scale and 9 items with a psychological scale. Items ask about the impact of MS on day-to-day life in the past two weeks. All items have 5 response options: 1 "not at all" to 5"extremely". Each of the two scales are scored by summing the responses across items, then converting to a 0-100 scale where 100 indicates greater impact of disease on daily function (worse health). This study measured the change from baseline at 8 weeks and 21 weeks.

Full Information

First Posted
May 14, 2008
Last Updated
February 22, 2021
Sponsor
University of Sheffield
Collaborators
Sheffield Teaching Hospitals NHS Foundation Trust, Walton Centre NHS Foundation Trust
search

1. Study Identification

Unique Protocol Identification Number
NCT00678496
Brief Title
Cognitive Behavioural Therapy Software for the Treatment of Depression in People With Multiple Sclerosis
Acronym
CoSMoS
Official Title
Computerised Cognitive Behavioural Therapy for Treatment of Depression in MS (CoSMoS): Clinical Trial Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Completed
Study Start Date
October 2008 (Actual)
Primary Completion Date
January 31, 2010 (Actual)
Study Completion Date
January 31, 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Sheffield
Collaborators
Sheffield Teaching Hospitals NHS Foundation Trust, Walton Centre NHS Foundation Trust

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Guidance issued by the United Kingdom (UK) National Institute for Health and Clinical Excellence (NICE) recommends the use of computerised cognitive behavioural therapy (CCBT) 'Beating the Blues' (BtB) in treatment of depression. However CCBT has not been designed specifically for use by people with Multiple Sclerosis (MS) and may not be effective or appropriate for use by people with physical disabilities or cognitive symptoms. There would therefore be value in conducting a trial of the effectiveness of CCBT for depression in people with MS. The aim of this pilot study is to test the feasibility of a randomised control trial (RCT) of CCBT for depression in people with MS. The objective is to undertake a pilot RCT of comparison of CCBT with usual care including 3 month follow up to identify a realistic patient recruitment rate and provide reliable estimates of other parameters needed for designing a definitive RCT including the sample size. Other outcomes to be measured include estimates of the effect on depression and quality of life. Participants will be assessed as experiencing clinical levels of depression and be recruited from two participating MS Centres. The outcomes of the study will be (1) preliminary indication of the impact of CCBT on depression in MS; and, (2) a well researched protocol for a definitive RCT of the effectiveness of CCBT in treating depression in people with MS.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression, Multiple Sclerosis
Keywords
CBT-software, Computerised Cognitive Behavioural Therapy, CCBT, Cognitive Therapy, Therapy, Computer-Assisted, Depression, Multiple Sclerosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
24 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
CBT software delivered at home or in a primary care facility (n=12)
Arm Title
2
Arm Type
Other
Arm Description
Treatment as usual (n=12)
Intervention Type
Other
Intervention Name(s)
CBT Software
Other Intervention Name(s)
Ultrasis Beating the Blues, Beating the Blues
Intervention Description
Beating the Blues is a CBT-based software package for patients with anxiety and/or depression. The CBT strategies used include: identifying thinking errors, challenging automatic negative thoughts, modifying attributional style and identifying core beliefs. The behavioural techniques used include graded exposure, sleep management, problem solving, task breakdown and activity scheduling. The programme consists of a 15 minute "Introduction to Therapy" video plus eight computer-interactive sessions of approximately 50 minutes each in duration. Each session consists of a mix of cognitive and behavioural strategies, which are customised to the patient's individual problems. The eight computer sessions are designed to be taken weekly, or thereabouts, and each session builds on the previous one.
Intervention Type
Other
Intervention Name(s)
Treatment as usual
Other Intervention Name(s)
Waiting list, Usual care, Treatment As Usual (TAU)
Intervention Description
Participants in the usual care arm are asked to refrain from accessing psychological services during their participation in the study, but may be prescribed anti-depressants or referred to a counsellor by their general practitioner.
Primary Outcome Measure Information:
Title
Change in Self-reported Symptoms of Depression, as Measured by Total BDI-II Score
Description
Beck Depression Inventory II-21 Item (BDI-II) - a self-report measure of severity of symptoms of depression. This is scored by summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The maximum total score is 63 (severe depression). The study reports change from baseline at 21 weeks.
Time Frame
21 weeks
Secondary Outcome Measure Information:
Title
Change in Disease-specific Quality of Life, Measured on the Multiple Sclerosis Impact Scale-29 Item (MSIS-29)
Description
The Multiple Sclerosis Impact Scale (MSIS-29) is a 29-item self-report measure with 20 items associated with a physical scale and 9 items with a psychological scale. Items ask about the impact of MS on day-to-day life in the past two weeks. All items have 5 response options: 1 "not at all" to 5"extremely". Each of the two scales are scored by summing the responses across items, then converting to a 0-100 scale where 100 indicates greater impact of disease on daily function (worse health). This study measured the change from baseline at 8 weeks and 21 weeks.
Time Frame
Eight weeks or on completion of CCBT (whichever is later), and three months thereafter.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged 18+ Diagnosis of MS confirmed by neurologist Beck Depression Inventory-II score of at least 14 on two consecutive occasions Not currently or within past three months receiving any treatment from a psychologist, psychotherapist or psychiatrist. Willingness to be randomised to CCBT, at home or primary care facility or treatment as usual. Exclusion Criteria: Unable to read or write English Beck Depression Inventory score of at least 29 on two consecutive occasions Active suicidal ideas Current or life-time diagnosis of any of the following: psychosis organic mental disorder; alcohol or drug dependency Kurtzke Expanded Disability Status Scale (EDSS) score of 8.5 or above Unable to use the CCBT package due to physical disability Unable to use the CCBT package due to cognitive symptoms (mini-mental state of 20 below or if, in the opinion of the study psychologist, the individual would be unlikely to benefit from CCBT)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cindy L Cooper, PhD
Organizational Affiliation
University of Sheffield
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Glenys D Parry, PhD
Organizational Affiliation
University of Sheffield
Official's Role
Study Chair
Facility Information:
Facility Name
Sheffield Teaching Hospitals NHS Foundation Trust
City
Sheffield
State/Province
South Yorkshire
ZIP/Postal Code
S10 3TG
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

Cognitive Behavioural Therapy Software for the Treatment of Depression in People With Multiple Sclerosis

We'll reach out to this number within 24 hrs